Emergent BioSolutions Reports First Quarter 2026 Financial Results
Emergent BioSolutions reported Q1 2026 revenue of $156.1 million, a 30% decrease year-over-year, but stated it was above the high-end of guidance. Adjusted EBITDA was $35.6 million. The company raised its full-year 2026 guidance for Adjusted EBITDA to $155-$175 million and Adjusted Net Income to $45-$65 million, while maintaining total revenue guidance of $720-$760 million. A new $150 million term loan facility was secured to refinance debt and reduce interest expense.
Key figures
- Eps
- 0.07
- Revenue
- 156.1
- Guidance
- FY26 Total Revenues $720-$760 (unchanged), Adjusted EBITDA $155-$175 (raised from $135-$155), Adjusted Net Income $45-$65 (raised from $25-$45), Q2 2026 Total Revenues $170M-$185M
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.